MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Zevra Therapeutics Inc

Closed

7.41 -3.39

Overview

Share price change

24h

Current

Min

7.25

Max

7.48

Key metrics

By Trading Economics

Income

-2.5M

-36M

Sales

8.3M

12M

EPS

-0.69

Profit margin

-296.762

Employees

59

EBITDA

13M

-17M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+204.51% upside

Dividends

By Dow Jones

Next Earnings

6 May 2025

Market Stats

By TradingEconomics

Market Cap

-7.3M

425M

Previous open

10.8

Previous close

7.41

Zevra Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

27 Feb 2025, 15:29 UTC

Acquisitions, Mergers, Takeovers

Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million

5 Aug 2024, 11:25 UTC

Major Market Movers

Zevra Shares Rally Premarket After FDA Panel Backs Arimoclomol

Peer Comparison

Price change

Zevra Therapeutics Inc Forecast

Price Target

By TipRanks

204.51% upside

12 Months Forecast

Average 22.29 USD  204.51%

High 25 USD

Low 18 USD

Based on 8 Wall Street analysts offering 12 month price targets forZevra Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

8

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$